Inhibition of cell growth in hct-116 human colorectal cancer cell line by sodium butyrate, a hdac inhibitor

Najmeh Amiri,1,* Flora forouzesh,2 Ehsan nazemalhosseini mojarad,3



Sodium butyrate (nabu), a histone deacetylase (hdac) inhibitor, is the byproduct of anaerobic microbial fermentation inside the gastrointestinal tract, and induce growth arrest and apoptosis in a variety of human cancer cells. the aim of this study is to investigate the anti proliferative and cytotoxicity effects of sodium butyrate against hct-116 colon cancer cell line.


Hct-116 cell line was maintained in dmem with 10% fetal bovine serum. 50 x103 cells were seeded into 96-well plates, and then treated with various concentrations of nabu (from 200mm to 6.25mm). after 24h, 48h and 72h incubation, the viability of cells was measured by mtt assay. the 50% inhibiting concentration ic50 were determined graphically. also cell morphology was assessed by invert microscope.


Our results showed that nabu induced of cell death in a dose- and time-dependent manner. mtt assays showed that treatment with nabu at high concentrations significantly inhibited the growth of hct-116 cells. ic50 for hct-116 cells were 25mm, 6.25mm and 6.25mm after 24h, 48h and 72h respectively. also after 24 and 48 hours, morphological changes were observed.


Our results may suggest that the gene expression which is contributed in cell proliferation and apoptosis may be changed under pressure of histone deacetylase inhibition due to nabu. therefore, an effective inhibitor of histone deacetylases may prove useful in the treatment of colorectal cancer. based on our findings, we propose that nabu may be useful as an anticancer drug.


Colon cancer nabu